The goal of Vicinitas Therapeutics is to emerge as the primary organization pioneering next-generation medications that profoundly impact the lives of patients. Their aim is to utilize their exclusive Deubiquitinase Targeting Chimera (DUBTAC) platform to reinstate the levels of unusually degraded proteins responsible for causing diseases, bringing about therapeutic advantages. Vicinitas Therapeutics will concentrate on creating distinct therapeutic solutions for diseases using their targeted protein stabilization platform, which aims to stabilize the levels of abnormally ubiquitinated and degraded proteins driving disease progression.